Matches in Wikidata for { <http://www.wikidata.org/entity/Q94409415> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q94409415 description "article scientifique publié en 2017" @default.
- Q94409415 description "wetenschappelijk artikel" @default.
- Q94409415 description "наукова стаття" @default.
- Q94409415 name "ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)" @default.
- Q94409415 name "ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)" @default.
- Q94409415 type Item @default.
- Q94409415 label "ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)" @default.
- Q94409415 label "ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)" @default.
- Q94409415 prefLabel "ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)" @default.
- Q94409415 prefLabel "ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)" @default.
- Q94409415 P1433 Q94409415-FAED4C23-C96F-48B7-AE4A-494217F9A763 @default.
- Q94409415 P1476 Q94409415-D261A267-CDC4-4941-9129-0B0F2F886EF3 @default.
- Q94409415 P2093 Q94409415-36DF4171-3FA2-4874-994C-24ED78A0CAE7 @default.
- Q94409415 P2093 Q94409415-82B2B00E-AD01-4027-8983-23CD10A060EA @default.
- Q94409415 P2093 Q94409415-91FCCAE6-A721-4D42-BFC9-04782523226A @default.
- Q94409415 P2093 Q94409415-CBABB25B-AD5B-4F71-BC64-15E95DAE2158 @default.
- Q94409415 P2093 Q94409415-E2BD3626-0F04-4D30-BE6B-5A82F2510805 @default.
- Q94409415 P304 Q94409415-90E608D6-9091-4B36-A3E2-11B5D1956677 @default.
- Q94409415 P31 Q94409415-EA453903-F276-421B-9A31-38A30F84D6AF @default.
- Q94409415 P356 Q94409415-28B64AC4-3BFC-4137-8884-2F4AD66449A6 @default.
- Q94409415 P433 Q94409415-6008AA2C-8139-4565-BA16-E02CDDF7DA33 @default.
- Q94409415 P478 Q94409415-E577D0EB-9D2F-4EDC-9205-81120E26340A @default.
- Q94409415 P50 Q94409415-052B1CDD-D01F-465A-B7BB-F30D01F68B8A @default.
- Q94409415 P50 Q94409415-098E95E7-EB34-49B3-9904-9DC28BCCEC0C @default.
- Q94409415 P50 Q94409415-0F1C3135-D024-454C-90FF-F7D3D4EB303F @default.
- Q94409415 P50 Q94409415-32B3364C-4ABA-45EF-88DC-A5C41CC03F12 @default.
- Q94409415 P50 Q94409415-89FF4A52-7213-4DEA-B4C3-BE8A2E238592 @default.
- Q94409415 P50 Q94409415-CB745AC9-E0CA-43BA-A85A-C153278A37E8 @default.
- Q94409415 P50 Q94409415-D9F26D27-9A25-4827-B170-30B7F9A628C3 @default.
- Q94409415 P50 Q94409415-DBC23F38-5131-418F-8CCE-DC8F51A46FD1 @default.
- Q94409415 P50 Q94409415-E2464117-D1EC-4CBC-A03C-7C4EB3428126 @default.
- Q94409415 P50 Q94409415-E9CB977A-D9A6-497E-822D-3242C77F286D @default.
- Q94409415 P577 Q94409415-414FF977-C1DF-4C1F-B5E6-634FDB5E8EEB @default.
- Q94409415 P921 Q94409415-9A5D2D47-622B-4252-B781-089150B58B94 @default.
- Q94409415 P921 Q94409415-DB2D26CA-F740-4280-AC56-0104BB450E2A @default.
- Q94409415 P932 Q94409415-A5CDCDA6-3FC0-4D82-A20C-7B284605B3D2 @default.
- Q94409415 P356 NOX168.044 @default.
- Q94409415 P1433 Q15724471 @default.
- Q94409415 P1476 "ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)" @default.
- Q94409415 P2093 "Nhung Nguyen" @default.
- Q94409415 P2093 "Stacy Green" @default.
- Q94409415 P2093 "William Yong" @default.
- Q94409415 P2093 "Xiao-Tang Kong" @default.
- Q94409415 P2093 "Yoon Choi" @default.
- Q94409415 P304 "vi12-vi12" @default.
- Q94409415 P31 Q13442814 @default.
- Q94409415 P356 "10.1093/NEUONC/NOX168.044" @default.
- Q94409415 P433 "Suppl 6" @default.
- Q94409415 P478 "19" @default.
- Q94409415 P50 Q114444384 @default.
- Q94409415 P50 Q114444392 @default.
- Q94409415 P50 Q114444426 @default.
- Q94409415 P50 Q42813170 @default.
- Q94409415 P50 Q47159504 @default.
- Q94409415 P50 Q59440413 @default.
- Q94409415 P50 Q59749173 @default.
- Q94409415 P50 Q86110874 @default.
- Q94409415 P50 Q89181819 @default.
- Q94409415 P50 Q91624773 @default.
- Q94409415 P577 "2017-11-06T00:00:00Z" @default.
- Q94409415 P921 Q282142 @default.
- Q94409415 P921 Q425088 @default.
- Q94409415 P932 "5693090" @default.